Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Ophthalmology

Free Subscription Articles published in J Ocul Pharmacol Ther Retrieve available abstracts of 219 articles: HTML format

Single Articles

April 2024
1. TRAN HDM, Ha TTX, Tran YH, Coroneo M, et al
   Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.
   J Ocul Pharmacol Ther. 2024 Apr 15. doi: 10.1089/jop.2023.0173.
   PubMed     Abstract available
   
   
   
2. HUSAIN S, Obert E, Singh S, Schnabolk G, et al
   Inhibition of HDAC1 and 3 in the Presence of Systemic Inflammation Reduces Retinal Degeneration in a Model of Dry Age-Related Macular Degeneration.
   J Ocul Pharmacol Ther. 2024 Apr 12. doi: 10.1089/jop.2023.0163.
   PubMed     Abstract available
   
   
   
3. YADAV KS, Bisen AC, Ishteyaque S, Sharma I, et al
   Solanum nigrum Toxicity and Its Neuroprotective Effect Against Retinal Ganglion Cell Death Through Modulation of Extracellular Matrix in a Glaucoma Rat Model.
   J Ocul Pharmacol Ther. 2024 Apr 11. doi: 10.1089/jop.2023.0089.
   PubMed     Abstract available
   
   
   
4. MISHRA A, Agrawal M, Tripathi A, Bhirud A, et al
   A Comparative Study on Efficacy of Intraocular Pressure Lowering of Two Fixed-Dose Antiglaucoma Drug Combination Brinzolamide-Brimonidine Versus Latanoprost-Timolol in Primary Open-Angle Glaucoma and Ocular Hypertension.
   J Ocul Pharmacol Ther. 2024 Apr 10. doi: 10.1089/jop.2023.0186.
   PubMed     Abstract available
   
   
   
5. DIAS PB, Rodrigues Parchen MDA, Wasilewski D
   Comparison of Proparacaine, Tetracaine, and Oxybuprocaine in Corneal Sensitivity Measurement.
   J Ocul Pharmacol Ther. 2024 Apr 8. doi: 10.1089/jop.2023.0148.
   PubMed     Abstract available
   
   
   
6. GARWEG JG, Pietzuch M, Mantel I, Ambresin A, et al
   Response to the Letter to the Editor by Michael Colucciello, MD, FASRS, Entitled "Steroid/Anti-VEGF Combination Therapy for Neovascular AMD".
   J Ocul Pharmacol Ther. 2024;40:199-200.
   PubMed    
   
   
   
7. NOVACK GD
   Eyes on New Product Development.
   J Ocul Pharmacol Ther. 2024;40:158-159.
   PubMed    
   
   
   
8. WATANABE M, Sato T, Umetsu A, Nishikiori N, et al
   Differential Effects of Benzalkonium Chloride on Human Trabecular Meshwork Cells Not Treated or Treated with Transforming Growth Factor-beta2 or Dexamethasone.
   J Ocul Pharmacol Ther. 2024;40:189-196.
   PubMed     Abstract available
   
   
   
9. GAO J, Wang Y, Han R, Li J, et al
   Elevated KDM4D Expression in Pterygium: Impact and Potential Inhibition by Lycium Barbarum Polysaccharide.
   J Ocul Pharmacol Ther. 2024;40:181-188.
   PubMed     Abstract available
   
   
   March 2024
10. CHENG Y, Liu G
    Evaluation of the Treatment Effects of Conditioned Medium from Human Orbital Adipose-Derived Stem Cells in a Corneal Alkali Burn Rabbit Model.
    J Ocul Pharmacol Ther. 2024 Mar 28. doi: 10.1089/jop.2023.0154.
    PubMed     Abstract available
    
    
    
11. CID-BERTOMEU P, Vilaltella M, Martinez M, Mir M, et al
    Topical Insulin for Ocular Surface Disease.
    J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2024.0016.
    PubMed     Abstract available
    
    
    
12. MURAKAMI Y, Imaizumi T, Hashizume K, Tezuka Y, et al
    Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity.
    J Ocul Pharmacol Ther. 2024 Mar 22. doi: 10.1089/jop.2023.0141.
    PubMed     Abstract available
    
    
    
13. YILMAZ OF, Sarmis A
    Relationship Between Conjunctival Corynebacterium and 5% Sheep Blood Agar.
    J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0010.
    PubMed    
    
    
    
14. COLUCCIELLO M
    Steroid/AntiVascular Endothelial Growth Factor Combination Therapy for Neovascular Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2024 Mar 6. doi: 10.1089/jop.2024.0013.
    PubMed    
    
    
    
15. LEE JH, Kim JH
    Impact of Prolonged Persisting Subretinal Fluid on the Outcome of Aflibercept Treatment in Neovascular Age-Related Macular Degeneration.
    J Ocul Pharmacol Ther. 2024;40:136-143.
    PubMed     Abstract available
    
    
    
16. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:109-110.
    PubMed    
    
    
    
17. FIGUS M, Giansanti F, Villani E, Alio JL, et al
    Chloroprocaine 3% Gel as a Novel Ocular Topical Anesthetic: Results from a Multicenter, Randomized Clinical Trial in Patients Undergoing Cataract Surgery.
    J Ocul Pharmacol Ther. 2024;40:117-125.
    PubMed     Abstract available
    
    
    February 2024
18. RUAN M, Wang R, He Y
    Novel Drug Delivery Systems for the Management of Fungal Keratitis.
    J Ocul Pharmacol Ther. 2024 Feb 23. doi: 10.1089/jop.2023.0161.
    PubMed     Abstract available
    
    
    January 2024
19. DIONNE E, Spadaro JZ, Atayde AMP, Kombo N, et al
    Antibiotic Prescribing Patterns Among U.S. Ophthalmologists and Optometrists from 2018 to 2021 in the Medicare Part D Database.
    J Ocul Pharmacol Ther. 2024 Jan 10. doi: 10.1089/jop.2023.0126.
    PubMed     Abstract available
    
    
    
20. ZHAN L, Tian X, Lin J, Zhang Y, et al
    The Therapeutic Role and Mechanism of Glabridin Under Aspergillus fumigatus Infection.
    J Ocul Pharmacol Ther. 2024;40:89-99.
    PubMed     Abstract available
    
    
    
21. TELFAH A, Al-Akhras MA, AlShheamat H, Mousa MS, et al
    Dissociation Kinetics and Antimicrobial Activity of Ofloxacin Antibiotic in Artificial Tears Via (1)H-NMR, Raman, and UV-Vis Spectroscopic Analysis.
    J Ocul Pharmacol Ther. 2024;40:78-88.
    PubMed     Abstract available
    
    
    
22. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2024;40:1-2.
    PubMed    
    
    
    
23. AJOUZ L, Hallak J, Naik R, Nguyen A, et al
    Evaluation of the Impact of Meibomian Gland Dysfunction Using a Novel Patient-Reported Outcome Instrument.
    J Ocul Pharmacol Ther. 2024;40:48-56.
    PubMed     Abstract available
    
    
    December 2023
24. ALMEIDA J, R Costa T, Vivas M, Monteiro C, et al
    Vitamin B(3) Supplementation for Optic Neuropathies: A Comprehensive Review.
    J Ocul Pharmacol Ther. 2023 Dec 27. doi: 10.1089/jop.2023.0125.
    PubMed     Abstract available
    
    
    
25. OGURA N, Fujisawa K, Kato M
    Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis.
    J Ocul Pharmacol Ther. 2023 Dec 27. doi: 10.1089/jop.2023.0132.
    PubMed     Abstract available
    
    
    
26. CAI C, Youssef AAA, Joshi PH, Varner C, et al
    Improved Topical Ophthalmic Natamycin Suspension for the Treatment of Fungal Keratitis.
    J Ocul Pharmacol Ther. 2023 Dec 20. doi: 10.1089/jop.2023.0092.
    PubMed     Abstract available
    
    
    
27. PIETZUCH M, Mantel I, Ambresin A, Tappeiner C, et al
    Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand.
    J Ocul Pharmacol Ther. 2023 Dec 20. doi: 10.1089/jop.2023.0105.
    PubMed     Abstract available
    
    
    
28. QIN G, Chen J, Li L, Qi Y, et al
    Effects of Diquafosol Sodium Ophthalmic Solution on Tear Film Matrix Metallopeptidase-9 and Corneal Nerve Density in Patients with Type 2 Diabetic Dry Eye.
    J Ocul Pharmacol Ther. 2023 Dec 13. doi: 10.1089/jop.2023.0098.
    PubMed     Abstract available
    
    
    
29. GALLI C, Bastia E, Hubatsch DA, Toris C, et al
    NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs.
    J Ocul Pharmacol Ther. 2023 Dec 12. doi: 10.1089/jop.2023.0102.
    PubMed     Abstract available
    
    
    
30. MEHTA NJ, Mehta SN
    Nanotechnology in Retinal Disease: Current Concepts and Future Directions.
    J Ocul Pharmacol Ther. 2023 Dec 5. doi: 10.1089/jop.2023.0083.
    PubMed     Abstract available
    
    
    
31. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:673-674.
    PubMed    
    
    
    
32. KORKMAZ I, Esen Baris M, Guven Yilmaz S, Palamar M, et al
    Effect of Cycloplegia on Anterior Segment Structures and Scleral Thickness in Emmetropic Eyes.
    J Ocul Pharmacol Ther. 2023;39:699-704.
    PubMed     Abstract available
    
    
    
33. MOLLER-HANSEN M, Utheim TP, Heegaard S
    Surgical Procedures in the Treatment of Dry Eye Disease.
    J Ocul Pharmacol Ther. 2023;39:692-698.
    PubMed     Abstract available
    
    
    November 2023
34. XIE Y, Wang X, Ji Z, Li G, et al
    The Effectiveness and Safety of Intravitreal Injections of Voriconazole in the Treatment of Fungal Endophthalmitis: A Systematic Review.
    J Ocul Pharmacol Ther. 2023 Nov 24. doi: 10.1089/jop.2023.0103.
    PubMed     Abstract available
    
    
    
35. KHOPADE AJ, Halder A, Patel V, Shah H, et al
    A Comparative Preclinical Evaluation of a Novel Difluprednate 0.04% BID Ophthalmic Solution and Marketed 0.05% QID Ophthalmic Emulsion.
    J Ocul Pharmacol Ther. 2023 Nov 6. doi: 10.1089/jop.2023.0047.
    PubMed     Abstract available
    
    
    
36. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:583-584.
    PubMed    
    
    
    
37. EVANS D, Kenyon K, Ousler G, Watson M, et al
    Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
    J Ocul Pharmacol Ther. 2023;39:600-610.
    PubMed     Abstract available
    
    
    
38. AJOUZ L, Nguyen A, Zhao C, Robinson MR, et al
    Exploring Signs and Symptoms Associated with Meibomian Gland Dysfunction for Use as Clinical Trial Endpoints.
    J Ocul Pharmacol Ther. 2023;39:611-621.
    PubMed     Abstract available
    
    
    October 2023
39. CHOUDHRY HS, Patel AM, Zhu A, Guttikonda S, et al
    Interspecialty Opioid Prescribing Patterns in Ophthalmology Following Declaration of a Public Health Emergency.
    J Ocul Pharmacol Ther. 2023 Oct 25. doi: 10.1089/jop.2023.0078.
    PubMed     Abstract available
    
    
    
40. HIRANI K, Bansinath M, Mittal R, Lemos JRN, et al
    Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval.
    J Ocul Pharmacol Ther. 2023 Oct 5. doi: 10.1089/jop.2023.0071.
    PubMed     Abstract available
    
    
    
41. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:475-476.
    PubMed    
    
    
    
42. MEEHAN SD, Neag E, Bhattacharya SK
    Glycerophospholipid Analysis of Optic Nerve Regeneration Models Indicate Potential Membrane Order Changes Associated with the Lipidomic Shifts.
    J Ocul Pharmacol Ther. 2023;39:519-529.
    PubMed     Abstract available
    
    
    September 2023
43. POLOPALLI S, Saha A, Niri P, Kumar M, et al
    ROCK Inhibitors as an Alternative Therapy for Corneal Grafting: A Systematic Review.
    J Ocul Pharmacol Ther. 2023 Sep 22. doi: 10.1089/jop.2023.0040.
    PubMed     Abstract available
    
    
    
44. BISWAS A, Choudhury AD, Agrawal S, Bisen AC, et al
    Recent Insights into the Etiopathogenesis of Diabetic Retinopathy and Its Management.
    J Ocul Pharmacol Ther. 2023 Sep 21. doi: 10.1089/jop.2023.0068.
    PubMed     Abstract available
    
    
    
45. ROWE-RENDLEMAN C, Eveleth D, Goldberg JL, Jurkunas U, et al
    Development of Anterior Segment Focused Biologic Therapies to Regenerate Corneal Tissue for the Treatment of Disease: Drug Development Experience.
    J Ocul Pharmacol Ther. 2023 Sep 21. doi: 10.1089/jop.2023.0044.
    PubMed     Abstract available
    
    
    
46. WANG P, Fan S, Hu X, Luo L, et al
    MG132, Attenuates the Retinal Vascular Injury Through the Upregulation of Nrf2 Expression.
    J Ocul Pharmacol Ther. 2023 Sep 20. doi: 10.1089/jop.2023.0053.
    PubMed     Abstract available
    
    
    
47. ABDELKADER H, Fatease AA, Fathalla Z
    Preformulation-Assisted Design of Ketorolac Tromethamine for Effective Ophthalmic Delivery.
    J Ocul Pharmacol Ther. 2023 Sep 7. doi: 10.1089/jop.2023.0066.
    PubMed     Abstract available
    
    
    
48. JIANG C, Yin X, Chang J, Liu G, et al
    Topical Administration of Bevacizumab to Facilitate the Functional Filtering Bleb After Trabeculectomy in the Rabbit.
    J Ocul Pharmacol Ther. 2023 Sep 5. doi: 10.1089/jop.2023.0046.
    PubMed     Abstract available
    
    
    
49. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:416-417.
    PubMed    
    
    
    
50. BAI J, Song Z, Li G, Dong L, et al
    Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Drugs for Coats' Disease Treatment: A Systematic Review.
    J Ocul Pharmacol Ther. 2023;39:418-429.
    PubMed     Abstract available
    
    
    
51. KESSLER LJ, Auffarth GU, Khoramnia R
    Functional and Morphological Responses to Fluocinolone Acetonide 0.19 mg in Noninfectious Uveitic Macular Edema Evaluated as the Area-Under-the-Curve.
    J Ocul Pharmacol Ther. 2023;39:449-455.
    PubMed     Abstract available
    
    
    August 2023
52. KHOPADE AJ, Halder A, Patel V, Upadhyay S, et al
    Preclinical Evaluation of a Novel Once-a-Day Brimonidine Ophthalmic Nanosuspension.
    J Ocul Pharmacol Ther. 2023 Aug 30. doi: 10.1089/jop.2023.0038.
    PubMed     Abstract available
    
    
    
53. JAFFRY M, Choudhry H, Aftab OM, Dastjerdi MH, et al
    Antibody-Drug Conjugates and Ocular Toxicity.
    J Ocul Pharmacol Ther. 2023 Aug 23. doi: 10.1089/jop.2023.0069.
    PubMed     Abstract available
    
    
    
54. GUO Z, Wei Z, Tong Y, Chen S, et al
    Efficacy and Safety Evaluation of Scleral Cross-Linking Using Genipin in the Treatment of Juvenile Guinea Pigs with High Myopia.
    J Ocul Pharmacol Ther. 2023 Aug 15. doi: 10.1089/jop.2023.0024.
    PubMed     Abstract available
    
    
    
55. VENKATESH S, Richardson M
    Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation.
    J Ocul Pharmacol Ther. 2023 Aug 15. doi: 10.1089/jop.2023.0050.
    PubMed     Abstract available
    
    
    
56. LIN J, Lu Z, Wang Y, Zhang J, et al
    Pharmacokinetics of Sirolimus Eye Drops Following Topical Ocular Administration in Rabbits.
    J Ocul Pharmacol Ther. 2023 Aug 9. doi: 10.1089/jop.2023.0035.
    PubMed     Abstract available
    
    
    
57. KUO HT, Yeh CY, Hsu AY, Ho JH, et al
    Clinical Efficacy of Omidenepag Isopropyl for Primary Open-Angle Glaucoma, Normal Tension Glaucoma, or Ocular Hypertension: A Meta-Analysis.
    J Ocul Pharmacol Ther. 2023 Aug 9. doi: 10.1089/jop.2023.0058.
    PubMed     Abstract available
    
    
    July 2023
58. CHO HJ, Kang KH, Yoon W, Lee J, et al
    Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
    J Ocul Pharmacol Ther. 2023 Jul 27. doi: 10.1089/jop.2023.0030.
    PubMed     Abstract available
    
    
    
59. HWANG JS, Kim J, You GE, Hong IH, et al
    In Vivo Electroporation Improves Retinal Delivery of Intravitreally Injected Exosomes.
    J Ocul Pharmacol Ther. 2023 Jul 25. doi: 10.1089/jop.2023.0016.
    PubMed     Abstract available
    
    
    
60. HU M, Veldman MB
    Intraocular Axon Regeneration in a Model of Penetrating Eye Injury.
    J Ocul Pharmacol Ther. 2023 Jul 24. doi: 10.1089/jop.2023.0048.
    PubMed     Abstract available
    
    
    
61. PINCHUK L
    The Development of a SIBS Shunt to Treat Glaucoma.
    J Ocul Pharmacol Ther. 2023 Jul 19. doi: 10.1089/jop.2023.0005.
    PubMed     Abstract available
    
    
    
62. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:362-364.
    PubMed    
    
    
    
63. SCHLATTER A, Hommer N, Kallab M, Stegmann H, et al
    Effect of Treatment with Topical Azithromycin or Oral Doxycycline on Tear Film Thickness in Patients with Meibomian Gland Dysfunction: A Randomized Controlled Trial.
    J Ocul Pharmacol Ther. 2023;39:371-378.
    PubMed     Abstract available
    
    
    
64. MALEK G
    Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for the Journal of Ocular Pharmacology and Therapeutics.
    J Ocul Pharmacol Ther. 2023;39:361.
    PubMed    
    
    
    
65. TSUGENO Y, Sato T, Watanabe M, Furuhashi M, et al
    Prostanoid FP and EP2 Receptor Agonists Induce Epithelial and Subepithelial Fibrogenetic Changes in Human Conjunctival Fibroblasts in Different Manners.
    J Ocul Pharmacol Ther. 2023;39:404-414.
    PubMed     Abstract available
    
    
    June 2023
66. XU W, Zhou P, Kansara ND, Frankfort BJ, et al
    Intraocular Pressure and Eyedrop Usage Reduction with Intracameral Bimatoprost Implant.
    J Ocul Pharmacol Ther. 2023 Jun 30. doi: 10.1089/jop.2023.0013.
    PubMed     Abstract available
    
    
    
67. GHONIEM DF, Abdelkawi SA, Fadel M, Abdel Fadeel D, et al
    Novel Photodynamic/Photothermal Treatment of Fungal Keratitis Using Rose Bengal-Loaded Polypyrrole-Gold Nanoparticles in Wistar Albino Rats.
    J Ocul Pharmacol Ther. 2023 Jun 30. doi: 10.1089/jop.2023.0004.
    PubMed     Abstract available
    
    
    
68. HIKAGE F, Watanabe M, Sato T, Umetsu A, et al
    Simultaneous Effects of a Selective EP2 Agonist, Omidenepag, and a Rho-Associated Coiled-Coil Containing Protein Kinase Inhibitor, Ripasudil, on Human Orbital Fibroblasts.
    J Ocul Pharmacol Ther. 2023 Jun 23. doi: 10.1089/jop.2023.0025.
    PubMed     Abstract available
    
    
    
69. XIANG A, He H, Yu H, Li A, et al
    Ocular Posterior Segment Distribution and Pharmacokinetics of Brimonidine After Intravitreal Administration in Guinea Pigs.
    J Ocul Pharmacol Ther. 2023 Jun 13. doi: 10.1089/jop.2023.0020.
    PubMed     Abstract available
    
    
    
70. ARCURI J, Elbaz A, Sharif NA, Bhattacharya SK, et al
    Ocular Treatments Targeting Separate Prostaglandin Receptors in Mice Exhibit Alterations in Intraocular Pressure and Optic Nerve Lipidome.
    J Ocul Pharmacol Ther. 2023 Jun 2. doi: 10.1089/jop.2023.0006.
    PubMed     Abstract available
    
    
    
71. KIM JG, An JH, Cho SY, Lee CE, et al
    Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications.
    J Ocul Pharmacol Ther. 2023 Jun 2. doi: 10.1089/jop.2022.0183.
    PubMed     Abstract available
    
    
    
72. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:301-302.
    PubMed    
    
    
    
73. 
    Correction to: Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes, by Obata et al. J. Ocul. Pharmacol. Ther 2023;39(3):225-228. DOI: 10.1089/jop.2022.0160.
    J Ocul Pharmacol Ther. 2023;39:359.
    PubMed    
    
    
    May 2023
74. GHOSH AK, Cesna R, Neverauskas D, Ziniauskaite A, et al
    Dietary Alcohol Consumption Elicits Corneal Toxicity Through the Generation of Cellular Oxidative Stress.
    J Ocul Pharmacol Ther. 2023 May 29. doi: 10.1089/jop.2022.0187.
    PubMed     Abstract available
    
    
    
75. ROY CHOWDHURY U, Pervan-Steel CL, Sheeler R, Sookdeo HK, et al
    Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive Agent.
    J Ocul Pharmacol Ther. 2023 May 17. doi: 10.1089/jop.2022.0184.
    PubMed     Abstract available
    
    
    
76. ZHAO A, Rasendran C, Aryal S, Yu J, et al
    Trends in Ophthalmological Patents, 2005-2020.
    J Ocul Pharmacol Ther. 2023 May 16. doi: 10.1089/jop.2022.0185.
    PubMed     Abstract available
    
    
    
77. VENANZI AW, Carmy-Bennun T, Marino FS, Ribeiro M, et al
    Context-Dependent Effects of the Ketogenic Diet on Retinal Ganglion Cell Survival and Axonal Regeneration After Optic Nerve Injury.
    J Ocul Pharmacol Ther. 2023 May 12. doi: 10.1089/jop.2023.0001.
    PubMed     Abstract available
    
    
    
78. WANG S
    Ribonucleic Acid (RNA) Therapeutics: Role of Long Noncoding RNAs in Ocular Vascular Diseases.
    J Ocul Pharmacol Ther. 2023;39:237-239.
    PubMed    
    
    
    
79. HUANG W, Huang L, Wen Z, Honkanen RA, et al
    The Antiangiogenic Effect and Ocular Pharmacology of Novel Modified Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Oxygen-Induced Retinopathy.
    J Ocul Pharmacol Ther. 2023;39:279-289.
    PubMed     Abstract available
    
    
    
80. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:235-236.
    PubMed    
    
    
    
81. LARSEN AC, Moller-Hansen M, Wiencke AK, Terslev L, et al
    Ultrasound-Guided Transcutaneous Injection in the Lacrimal Gland: A Description of Sonoanatomy and Technique.
    J Ocul Pharmacol Ther. 2023;39:275-278.
    PubMed     Abstract available
    
    
    April 2023
82. WIGGINS SV, Schreiner R, Ferreira J, Marmorstein AD, et al
    Carbonic Anhydrase Inhibitor Modulation of Intraocular Pressure Is Independent of Soluble Adenylyl Cyclase.
    J Ocul Pharmacol Ther. 2023 Apr 25. doi: 10.1089/jop.2022.0180.
    PubMed     Abstract available
    
    
    
83. DAULL P, Garrigue JS, Liang H, Baudouin C, et al
    Use of a Cationic Emulsion of Latanoprost to Treat Glaucoma Patients with Ocular Surface Disease: A Preclinical Review.
    J Ocul Pharmacol Ther. 2023 Apr 4. doi: 10.1089/jop.2022.0155.
    PubMed     Abstract available
    
    
    
84. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:189-190.
    PubMed    
    
    
    March 2023
85. AHMAD S, Wright KN, VonCannon JL, Ferrario CM, et al
    Internalization of Angiotensin-(1-12) in Adult Retinal Pigment Epithelial-19 Cells.
    J Ocul Pharmacol Ther. 2023 Mar 21. doi: 10.1089/jop.2022.0139.
    PubMed     Abstract available
    
    
    
86. SHILPASHREE PS, Ravi T, Thanuja MY, Anupama C, et al
    Grading the Severity of Damage to the Perijunctional Actomyosin Ring and Zonula Occludens-1 of the Corneal Endothelium by Ensemble Learning Methods.
    J Ocul Pharmacol Ther. 2023 Mar 17. doi: 10.1089/jop.2022.0154.
    PubMed     Abstract available
    
    
    
87. PERAZA MA, Hurst S, Huang W, Buetow BS, et al
    Ocular Safety and Toxicokinetics of Bevacizumab-bvzr (Zirabev), a Bevacizumab Biosimilar, Administered to Cynomolgus Monkeys by Intravitreal Injection.
    J Ocul Pharmacol Ther. 2023 Mar 7. doi: 10.1089/jop.2022.0059.
    PubMed     Abstract available
    
    
    
88. WILSON SE
    Topical Losartan: Practical Guidance for Clinical Trials in the Prevention and Treatment of Corneal Scarring Fibrosis and Other Eye Diseases and Disorders.
    J Ocul Pharmacol Ther. 2023 Mar 6. doi: 10.1089/jop.2022.0174.
    PubMed     Abstract available
    
    
    
89. KHA CX, Nava I, Tseng KA
    V-ATPase Regulates Retinal Progenitor Cell Proliferation During Eye Regrowth in Xenopus.
    J Ocul Pharmacol Ther. 2023 Mar 3. doi: 10.1089/jop.2022.0085.
    PubMed     Abstract available
    
    
    
90. OBATA S, Kakinoki M, Sawada O, Kawamoto I, et al
    Duration of Vascular Endothelial Growth Factor Suppression After Intravitreal Injection of Brolucizumab and Aflibercept in Macaque Eyes.
    J Ocul Pharmacol Ther. 2023 Mar 2. doi: 10.1089/jop.2022.0160.
    PubMed     Abstract available
    
    
    
91. TERSI N, Kassumeh S, Ohlmann A, Strehle L, et al
    Pharmacological Therapy of Proliferative Vitreoretinopathy: Systematic In Vitro Comparison of 36 Pharmacological Agents.
    J Ocul Pharmacol Ther. 2023;39:148-158.
    PubMed     Abstract available
    
    
    
92. PEREZ VL, Mah FS, Willcox M, Pflugfelder S, et al
    Anti-Inflammatories in the Treatment of Dry Eye Disease: A Review.
    J Ocul Pharmacol Ther. 2023;39:89-101.
    PubMed     Abstract available
    
    
    
93. GAUTAM M, Gupta R, Singh P, Verma V, et al
    Intracameral Drug Delivery: A Review of Agents, Indications, and Outcomes.
    J Ocul Pharmacol Ther. 2023;39:102-116.
    PubMed     Abstract available
    
    
    
94. NOVACK GD
    Eyes on New Product Development.
    J Ocul Pharmacol Ther. 2023;39:87-88.
    PubMed    
    
    
    
95. LIU W, Lin T, Gong L
    ZD6474 Attenuates Fibrosis and Inhibits Neovascularization in Human Pterygium by Suppressing AKT-mTOR Signaling Pathway.
    J Ocul Pharmacol Ther. 2023;39:128-138.
    PubMed     Abstract available
    
    
    February 2023
96. ZHOU T, Li X, Yang J, Xia H, et al
    Ocular Pharmacokinetic Properties of Intravitreally Injected Aflibercept in Rabbits After Using Brinzolamide/Timolol Eye Drops.
    J Ocul Pharmacol Ther. 2023 Feb 13. doi: 10.1089/jop.2022.0146.
    PubMed     Abstract available
    
    
    
97. NAIR S, Zhu A, Jaffry M, Choudhry H, et al
    Povidone-Iodine Adverse Effects and Alternatives for Ocular Procedures.
    J Ocul Pharmacol Ther. 2023 Feb 10. doi: 10.1089/jop.2022.0122.
    PubMed     Abstract available
    
    
    
98. WU P, Wang Z, Liang L, Chen B, et al
    Characteristics of Mitomycin C-Loaded Peptide Hydrogel In Vitro and Antiscarring Effects in Rat Ocular Injury Model.
    J Ocul Pharmacol Ther. 2023 Feb 1. doi: 10.1089/jop.2022.0102.
    PubMed     Abstract available
    
    
    January 2023
99. KUMAR A, Chaurasiya D, Sultan S, Soni D, et al
    Therapeutic Profile of Human Umbilical Cord Blood Serum and Autologous Serum Therapies in Treatment of Ocular Surface Disorders: A Pilot Study.
    J Ocul Pharmacol Ther. 2023 Jan 6. doi: 10.1089/jop.2022.0107.
    PubMed     Abstract available
    
    
    
100. STURDIVANT J, Williams SS, Ina M, Weksler M, et al
     Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates.
     J Ocul Pharmacol Ther. 2023 Jan 4. doi: 10.1089/jop.2022.0129.
     PubMed     Abstract available
     
     
     
101. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2023;39:1-2.
     PubMed    
     
     
     
102. EOM Y, Yoon KC, Kim HK, Song JS, et al
     A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
     J Ocul Pharmacol Ther. 2023;39:27-35.
     PubMed     Abstract available
     
     
     
103. WEINREB RN, Bacharach J, Brubaker JW, Medeiros FA, et al
     Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies.
     J Ocul Pharmacol Ther. 2023;39:55-62.
     PubMed     Abstract available
     
     
     
104. CORTINA ME, Benozzi G, Orman B
     Hyperopic LASIK Enhanced by Pharmacological Treatment of Presbyopia.
     J Ocul Pharmacol Ther. 2023;39:48-54.
     PubMed     Abstract available
     
     
     December 2022
105. NOGUCHI JL, Seu MY, Qiao JB, Tan IR, et al
     Kaempferol Protects Against Retinal Photoreceptor Degeneration in a Mouse Model of Light-Induced Retinal Injury.
     J Ocul Pharmacol Ther. 2022 Dec 14. doi: 10.1089/jop.2022.0128.
     PubMed     Abstract available
     
     
     
106. EOM Y, Song JS, Kim HM
     Effectiveness of Topical Cyclosporin A 0.1%, Diquafosol Tetrasodium 3%, and Their Combination, in Dry Eye Disease.
     J Ocul Pharmacol Ther. 2022;38:682-694.
     PubMed     Abstract available
     
     
     November 2022
107. PEARCE JG, Naunton M, Maddess T
     A Literature-Based Review and Analysis of the Pharmacodynamics of the Dose Frequency of Topical 0.3% Ciprofloxacin and 0.3% Ofloxacin in the Day-1 Treatment of Bacterial Keratitis.
     J Ocul Pharmacol Ther. 2022 Nov 29. doi: 10.1089/jop.2022.0110.
     PubMed     Abstract available
     
     
     
108. CHARTRAND NA, Lau CK, Parsons MT, Handlon JJ, et al
     Ocular Side Effects of Bisphosphonates: A Review of Literature.
     J Ocul Pharmacol Ther. 2022 Nov 21. doi: 10.1089/jop.2022.0094.
     PubMed     Abstract available
     
     
     
109. KONG W, Tao Y, Fan Q, Xie L, et al
     Changes and Treatment Prognosis of Aqueous Humor Cytokine Concentrations of Patients with Acquired Immune Deficiency Syndrome Complicated by Cytomegalovirus Retinitis.
     J Ocul Pharmacol Ther. 2022 Nov 15. doi: 10.1089/jop.2022.0012.
     PubMed     Abstract available
     
     
     
110. HAKIM R, Patel N, Veryovkin I, Gaynes BI, et al
     Effect of Age and Viscosity on Duration of Corneal Anesthesia with Topical 2% Lidocaine Administration.
     J Ocul Pharmacol Ther. 2022 Nov 14. doi: 10.1089/jop.2022.0076.
     PubMed     Abstract available
     
     
     
111. RAHMAN SNR, Goswami A, Sree A, Jala A, et al
     Dual Delivery of Cyclosporin A and Etodolac Using Polymeric Nanocapsules in a Rabbit Eye Model: Ocular Biodistribution and Pharmacokinetic Study.
     J Ocul Pharmacol Ther. 2022 Nov 10. doi: 10.1089/jop.2022.0092.
     PubMed     Abstract available
     
     
     
112. ANUPAMA C, Shettar A, Ranganath SH, Srinivas SP, et al
     Experimental Oxidative Stress Breaks Down the Barrier Function of the Corneal Endothelium.
     J Ocul Pharmacol Ther. 2022 Nov 8. doi: 10.1089/jop.2022.0093.
     PubMed     Abstract available
     
     
     
113. LINDSTROM RL, Lewis AE, Holland EJ, Sheppard JD, et al
     Phase 2, Randomized, Open-Label Parallel-Group Study of Two Dosing Regimens of Netarsudil for the Treatment of Corneal Edema Due to Fuchs Corneal Dystrophy.
     J Ocul Pharmacol Ther. 2022 Nov 3. doi: 10.1089/jop.2022.0069.
     PubMed     Abstract available
     
     
     
114. LABETOULLE M, Mortemousque B
     Performance and Safety of a Sodium Hyaluronate Tear Substitute with Polyethylene Glycol in Dry Eye Disease: A Multicenter, Investigator-Masked, Randomized, Noninferiority Trial.
     J Ocul Pharmacol Ther. 2022;38:607-616.
     PubMed     Abstract available
     
     
     
115. HU J, Ma Q, Xin C, Jiao Y, et al
     Analysis of Drug Clinical Trials for Eye Diseases in China.
     J Ocul Pharmacol Ther. 2022;38:645-653.
     PubMed     Abstract available
     
     
     
116. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:592-593.
     PubMed    
     
     
     
117. ACET Y, Sarikaya S
     Another Etiological Factor of Meibomian Gland Loss in Patients with Polycystic Ovary Syndrome: Inflammation.
     J Ocul Pharmacol Ther. 2022;38:626-634.
     PubMed     Abstract available
     
     
     October 2022
118. SAKATA R, Fujishiro T, Saito H, Nakamura N, et al
     Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma.
     J Ocul Pharmacol Ther. 2022 Oct 31. doi: 10.1089/jop.2022.0096.
     PubMed     Abstract available
     
     
     
119. AL-DWAIRI R, Ahmad AA, Aleshawi A, Bani-Salameh A, et al
     Optical and Physical Properties of Silicone Oil Extracted from the Vitreous of Patients Who Underwent Vitrectomy for Retinal Detachment.
     J Ocul Pharmacol Ther. 2022 Oct 31. doi: 10.1089/jop.2022.0081.
     PubMed     Abstract available
     
     
     
120. CHO H, Seo Y, Han SH, Han J, et al
     Factors Related to Axial Length Elongation in Myopic Children Who Received 0.05% Atropine Treatment.
     J Ocul Pharmacol Ther. 2022 Oct 21. doi: 10.1089/jop.2022.0036.
     PubMed     Abstract available
     
     
     
121. TORRENS I, Ganza A, Hernandez G, Gonzalo A, et al
     Ocular Biodistribution of Once-Daily 0.6% Bilastine Eye Drops Reveals Highest Levels in Conjunctiva Up to 24 h Postadministration.
     J Ocul Pharmacol Ther. 2022 Oct 21. doi: 10.1089/jop.2022.0024.
     PubMed     Abstract available
     
     
     
122. CHEN X, Zhao Y, You S, Xia Q, et al
     7,8-Dihydroxyflavone Simultaneously Provides Neuroprotection of Retinal Explants and Proangiogenesis of Human Umbilical Vein Endothelial Cells via the Tropomyosin-Related Kinase Receptor B Signaling Pathway In Vitro.
     J Ocul Pharmacol Ther. 2022 Oct 18. doi: 10.1089/jop.2022.0064.
     PubMed     Abstract available
     
     
     
123. THANUJA MY, Ranganath SH, Srinivas SP
     Role of Oxidative Stress in the Disruption of the Endothelial Apical Junctional Complex During Corneal Cold Storage.
     J Ocul Pharmacol Ther. 2022 Oct 17. doi: 10.1089/jop.2022.0082.
     PubMed     Abstract available
     
     
     
124. KAO JH, Lai TT, Lu CH, Lan TY, et al
     Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population.
     J Ocul Pharmacol Ther. 2022 Oct 7. doi: 10.1089/jop.2022.0060.
     PubMed     Abstract available
     
     
     
125. THANUJA MY, Ranganath SH, Bonanno JA, Srinivas SP, et al
     Nanoliposomes for Sensing Local Osmolarity of the Tear Film on the Corneal Surface.
     J Ocul Pharmacol Ther. 2022;38:549-560.
     PubMed     Abstract available
     
     
     
126. CHUNG H, Ha Y, Kim YH, Kim DH, et al
     Ocular Distribution and Pharmacokinetics of 8-Oxo-2'-Deoxyguanosine: A Novel Therapeutic Candidate of Ocular Surface Diseases.
     J Ocul Pharmacol Ther. 2022;38:561-566.
     PubMed     Abstract available
     
     
     
127. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:527-528.
     PubMed    
     
     
     
128. LIN T, Feng C, Bi Y, Lu P, et al
     Lidocaine Hydrochloride Gel for Ocular Surface Anesthesia: Pharmacokinetic Evaluation and Randomized Placebo-Controlled Trial in China.
     J Ocul Pharmacol Ther. 2022;38:567-575.
     PubMed     Abstract available
     
     
     September 2022
129. KUCUKODUK A, Durmus IM, Aksoy M, Karakurt S, et al
     Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line.
     J Ocul Pharmacol Ther. 2022 Sep 30. doi: 10.1089/jop.2022.0053.
     PubMed     Abstract available
     
     
     
130. WILSON SE
     Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and Disease.
     J Ocul Pharmacol Ther. 2022 Sep 26. doi: 10.1089/jop.2022.0088.
     PubMed     Abstract available
     
     
     
131. TOUTOUNCHIAN S, Ahmadbeigi N, Mansouri V
     Retinal and Choroidal Neovascularization Antivascular Endothelial Growth Factor Treatments: The Role of Gene Therapy.
     J Ocul Pharmacol Ther. 2022 Sep 19. doi: 10.1089/jop.2022.0022.
     PubMed     Abstract available
     
     
     
132. NUSANTI S, Sari RI, Siregar NC, Sidik M, et al
     The Effect of Citicoline on Ethambutol Optic Neuropathy: Histopathology and Immunohistochemistry Analysis of Retina Ganglion Cell Damage Level in Rat Model.
     J Ocul Pharmacol Ther. 2022 Sep 8. doi: 10.1089/jop.2022.0005.
     PubMed     Abstract available
     
     
     
133. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:469-470.
     PubMed    
     
     
     
134. KUSTRYN T, Zadorozhnyy O, Nasinnyk I, Korol A, et al
     Photodynamic Therapy with Chlorin e6 Derivative for Chronic Central Serous Chorioretinopathy (Pilot Study).
     J Ocul Pharmacol Ther. 2022;38:505-512.
     PubMed     Abstract available
     
     
     July 2022
135. FAN S, Gulati V, Neely DG, Andersen A, et al
     Changes in Ocular Biometric Parameters Over a 24-Hour Period in Ocular Hypertensive Patients.
     J Ocul Pharmacol Ther. 2022 Jul 19. doi: 10.1089/jop.2021.0132.
     PubMed     Abstract available
     
     
     
136. VERHOEVEN R, Uram M, Schupp A, Rasmussen S, et al
     Early Nonclinical and Clinical Development of AG-920, a Repurposed Topical Ocular Anesthetic.
     J Ocul Pharmacol Ther. 2022 Jul 18. doi: 10.1089/jop.2022.0026.
     PubMed     Abstract available
     
     
     
137. BROOKS D, Linares-Alba MA, Garcia-Santisteban R, Xie E, et al
     Pharmacokinetics of Sirolimus in a Novel Liposome Delivery System in Selected Ocular Tissues and Plasma Following a Single Subconjunctival Injection in Dutch Belted Rabbits.
     J Ocul Pharmacol Ther. 2022 Jul 14. doi: 10.1089/jop.2022.0030.
     PubMed     Abstract available
     
     
     
138. BASTIA E, Sgambellone S, Lucarini L, Provensi G, et al
     NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia/Reperfusion Injury of Optic Nerve and Retina in Rabbits.
     J Ocul Pharmacol Ther. 2022 Jul 4. doi: 10.1089/jop.2022.0004.
     PubMed     Abstract available
     
     
     
139. POLAT HK, Kurt N, Aytekin E, Akdag Cayli Y, et al
     Design of Besifloxacin HCl-Loaded Nanostructured Lipid Carriers: In Vitro and Ex Vivo Evaluation.
     J Ocul Pharmacol Ther. 2022;38:412-423.
     PubMed     Abstract available
     
     
     June 2022
140. POLAT HK, Kurt N, Aytekin E, Bozdag Pehlivan S, et al
     Novel Drug Delivery Systems to Improve the Treatment of Keratitis.
     J Ocul Pharmacol Ther. 2022 Jun 28. doi: 10.1089/jop.2021.0127.
     PubMed     Abstract available
     
     
     
141. NOVACK GD
     Eyes on New Product Development: Long-Acting Ocular Drug Delivery Technologies Addressing Unmet Needs in Ophthalmology.
     J Ocul Pharmacol Ther. 2022 Jun 28. doi: 10.1089/jop.2022.29093.
     PubMed    
     
     
     
142. SHAO Z, Chwa M, Atilano SR, Park J, et al
     The Transcriptome Profile of Retinal Pigment Epithelium and Muller Cell Lines Protected by Risuteganib Against Hydrogen Peroxide Stress.
     J Ocul Pharmacol Ther. 2022 Jun 22. doi: 10.1089/jop.2022.0015.
     PubMed     Abstract available
     
     
     
143. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:327-328.
     PubMed    
     
     
     
144. JACOBI C, Angstmann-Mehr S, Lange A, Kaercher T, et al
     A Water-Free Omega-3 Fatty Acid Eye Drop Formulation for the Treatment of Evaporative Dry Eye Disease: A Prospective, Multicenter Noninterventional Study.
     J Ocul Pharmacol Ther. 2022;38:348-353.
     PubMed     Abstract available
     
     
     
145. CASTRO NG, Cohen R, Vazquez M
     Re: "Organ-On-A-Chip Technologies for Advanced Blood-Retinal Barrier Models," by Ragelle et al.
     J Ocul Pharmacol Ther. 2022;38:329-330.
     PubMed    
     
     
     May 2022
146. LEDBETTER EC, Badanes ZI, Chan RX, Donohue LK, et al
     Comparative Efficacy of Topical Ophthalmic Ganciclovir and Oral Famciclovir in Cats with Experimental Ocular Feline Herpesvirus-1 Epithelial Infection.
     J Ocul Pharmacol Ther. 2022 May 25. doi: 10.1089/jop.2022.0001.
     PubMed     Abstract available
     
     
     
147. ZHOU J, Huang Q, Wang L, Li E, et al
     Autophagy Protects Ocular Surface Against Overactivated Inflammation by Degrading Retinoic Acid-Induced Gene-I in Human Conjunctival Epithelial Cells.
     J Ocul Pharmacol Ther. 2022 May 25. doi: 10.1089/jop.2021.0121.
     PubMed     Abstract available
     
     
     
148. INOUE K, Shiokawa M, Kunimatsu-Sanuki S, Nozaki N, et al
     One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma.
     J Ocul Pharmacol Ther. 2022 May 25. doi: 10.1089/jop.2021.0122.
     PubMed     Abstract available
     
     
     
149. LOBERG LI, Henriques TA, Johnson JK, Miller PE, et al
     Characterization and Potential Mitigation of Corneal Effects in Nonclinical Toxicology Studies in Animals Administered Depatuxizumab Mafodotin.
     J Ocul Pharmacol Ther. 2022 May 10. doi: 10.1089/jop.2022.0006.
     PubMed     Abstract available
     
     
     
150. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:269-270.
     PubMed    
     
     
     April 2022
151. CHOUDHARY M, Ildefonso CJ, Lewin AS, Malek G, et al
     Gene Delivery of a Caspase Activation and Recruitment Domain Improves Retinal Pigment Epithelial Function and Modulates Inflammation in a Mouse Model with Features of Dry Age-Related Macular Degeneration.
     J Ocul Pharmacol Ther. 2022 Apr 19. doi: 10.1089/jop.2022.0002.
     PubMed     Abstract available
     
     
     
152. FOGAGNOLO P, Romano D, De Ruvo V, Sabella P, et al
     Clinical Efficacy of an Eyedrop Containing Hyaluronic Acid and Ginkgo Biloba in the Management of Dry Eye Disease Induced by Cataract Surgery.
     J Ocul Pharmacol Ther. 2022 Apr 18. doi: 10.1089/jop.2021.0123.
     PubMed     Abstract available
     
     
     
153. GHOSN C, Rajagopalan L, Ugarte S, Mistry S, et al
     Intraocular Pressure-Lowering Efficacy of a Sustained-Release Bimatoprost Implant in Dog Eyes Pretreated with Selective Laser Trabeculoplasty.
     J Ocul Pharmacol Ther. 2022 Apr 18. doi: 10.1089/jop.2021.0104.
     PubMed     Abstract available
     
     
     
154. KUTLUTURK G, Altan C, Yasar T
     Effects of Topical Antiglaucomatous Medications on Conjunctival Thickness: A Prospective Anterior Segment Optical Coherence Tomography Study.
     J Ocul Pharmacol Ther. 2022 Apr 11. doi: 10.1089/jop.2021.0105.
     PubMed     Abstract available
     
     
     
155. MUYA L, Kansara V, Cavet ME, Ciulla T, et al
     Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina.
     J Ocul Pharmacol Ther. 2022 Apr 11. doi: 10.1089/jop.2021.0090.
     PubMed     Abstract available
     
     
     
156. GHOSH AK, Bacellar-Galdino M, Iqbal S, Pappenhagen NE, et al
     Topical Porphyrin Antioxidant Protects Against Ocular Surface Pathology in a Novel Rabbit Model for Particulate Matter-Induced Dry Eye Disease.
     J Ocul Pharmacol Ther. 2022 Apr 4. doi: 10.1089/jop.2021.0131.
     PubMed     Abstract available
     
     
     
157. OSORNO LL, Mosley RJ, Poley PL, Bowers J, et al
     Sustained Release of Antibody-Conjugated DNA Nanocarriers from a Novel Injectable Hydrogel for Targeted Cell Depletion to Treat Cataract Posterior Capsule Opacification.
     J Ocul Pharmacol Ther. 2022 Apr 4. doi: 10.1089/jop.2021.0111.
     PubMed     Abstract available
     
     
     
158. STONEX T, Salmon JH, Adler KB, Gilger BC, et al
     Peptide Inhibitors of MARCKS Suppress Endotoxin Induced Uveitis in Rats.
     J Ocul Pharmacol Ther. 2022;38:223-231.
     PubMed     Abstract available
     
     
     
159. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:201-202.
     PubMed    
     
     
     March 2022
160. LELYTE I, Ahmed Z, Kaja S, Kalesnykas G, et al
     Structure-Function Relationships in the Rodent Streptozotocin-Induced Model for Diabetic Retinopathy: A Systematic Review.
     J Ocul Pharmacol Ther. 2022 Mar 22. doi: 10.1089/jop.2021.0128.
     PubMed     Abstract available
     
     
     
161. ZHANG E, Gupta S, Olson E, Sinha PR, et al
     Effects of Regular/Dilute Proparacaine Anesthetic Eye Drops in Combination with Ophthalmic Antibiotics on Corneal Wound Healing.
     J Ocul Pharmacol Ther. 2022 Mar 11. doi: 10.1089/jop.2021.0116.
     PubMed     Abstract available
     
     
     
162. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:123-124.
     PubMed    
     
     
     
163. LIAO CH, Tseng CL, Lin SL, Liang CL, et al
     MicroRNA Therapy for Dry Eye Disease.
     J Ocul Pharmacol Ther. 2022;38:125-132.
     PubMed     Abstract available
     
     
     February 2022
164. GARCIA-MEDINA JJ, Benitez-Del-Castillo J, Rodriguez-Agirretxe I, Lopez-Lopez F, et al
     Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
     J Ocul Pharmacol Ther. 2022 Feb 28. doi: 10.1089/jop.2021.0099.
     PubMed     Abstract available
     
     
     
165. WIRTA DL, Kuwayama Y, Lu F, Shao H, et al
     Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study.
     J Ocul Pharmacol Ther. 2022 Feb 15. doi: 10.1089/jop.2021.0077.
     PubMed     Abstract available
     
     
     
166. GUPTA S, Shyamsundar K, Agrawal M, Vichare N, et al
     Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
     J Ocul Pharmacol Ther. 2022 Feb 8. doi: 10.1089/jop.2021.0098.
     PubMed     Abstract available
     
     
     
167. KIM JH, Kim JW, Kim CG
     Difference Between the Incidence of Retinal Fluid Subtypes and Their Association with Visual Outcomes According to the Types of Macular Neovascularization in a Korean Population.
     J Ocul Pharmacol Ther. 2022 Feb 3. doi: 10.1089/jop.2021.0103.
     PubMed     Abstract available
     
     
     January 2022
168. HUANG HM, Kuo HK, Chiang WY, Wu PC, et al
     Combination Therapy with Intravitreal Triamcinolone Acetonide and Oral Levodopa for the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy: A Pilot Study.
     J Ocul Pharmacol Ther. 2022 Jan 19. doi: 10.1089/jop.2021.0081.
     PubMed     Abstract available
     
     
     
169. ZHANG Q, Zhang H, Qin G, Wu Y, et al
     Impact of Diquafosol Ophthalmic Solution on Tear Film and Dry Eye Symptom in Type 2 Diabetic Dry Eye: A Pilot Study.
     J Ocul Pharmacol Ther. 2022 Jan 19. doi: 10.1089/jop.2021.0083.
     PubMed     Abstract available
     
     
     
170. RAJ SINGH TR
     Call for Special Issue Papers: Ocular Drug Delivery Technology Special Issue.
     J Ocul Pharmacol Ther. 2022;38:122.
     PubMed    
     
     
     
171. MAHON N, Slater K, O'Brien J, Alvarez Y, et al
     Discovery and Development of the Quininib Series of Ocular Drugs.
     J Ocul Pharmacol Ther. 2022;38:33-42.
     PubMed     Abstract available
     
     
     
172. HUANG W, Huang L, Li W, Saglam MS, et al
     Once-Daily Topical Phosphosulindac Is Efficacious in the Treatment of Dry Eye Disease: Studies in Rabbit Models of Its Main Clinical Subtypes.
     J Ocul Pharmacol Ther. 2022;38:102-113.
     PubMed     Abstract available
     
     
     
173. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2022;38:1-2.
     PubMed    
     
     
     December 2021
174. BEHERA G, Nagaraj GA, Thirunavukarasu SC, Jayaraman R, et al
     Effect of Blood Pressure Reduction on Intraocular Pressure and Ophthalmic Artery Blood Flow Velocity in Hypertension.
     J Ocul Pharmacol Ther. 2021 Dec 29. doi: 10.1089/jop.2021.0096.
     PubMed     Abstract available
     
     
     
175. LIMON U, Sezgin Akcay BI
     Add-On Effect of Simultaneous Intravitreal Dexamethasone to Intravitreal Bevacizumab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion.
     J Ocul Pharmacol Ther. 2021 Dec 29. doi: 10.1089/jop.2021.0100.
     PubMed     Abstract available
     
     
     
176. ARAD D, Komoron S, Pe'er O, Sebbag L, et al
     Mucoadhesive Polymers Enhance Ocular Drug Delivery: Proof of Concept Study with 0.5% Tropicamide in Dogs.
     J Ocul Pharmacol Ther. 2021 Dec 28. doi: 10.1089/jop.2021.0091.
     PubMed     Abstract available
     
     
     
177. YANG L, Yu P, Chen M, Lei B, et al
     Mammalian Target of Rapamycin Inhibitor Rapamycin Alleviates 7-Ketocholesterol Induced Inflammatory Responses and Vascular Endothelial Growth Factor Elevation by Regulating MAPK Pathway in Human Retinal Pigment Epithelium Cells.
     J Ocul Pharmacol Ther. 2021 Dec 21. doi: 10.1089/jop.2021.0082.
     PubMed     Abstract available
     
     
     
178. FUKUDA M, Takeda N, Ishida H, Seki Y, et al
     Benzalkonium Chloride-Induced Corneal Epithelial Injury in Rabbit Reduced by Rebamipide.
     J Ocul Pharmacol Ther. 2021 Dec 21. doi: 10.1089/jop.2021.0052.
     PubMed     Abstract available
     
     
     
179. ARENDT NIELSEN T, Sega R, Uggerhoj Andersen C, Vorum H, et al
     Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.
     J Ocul Pharmacol Ther. 2021 Dec 16. doi: 10.1089/jop.2021.0055.
     PubMed     Abstract available
     
     
     
180. KARAMI TK, Hailu S, Feng S, Graham R, et al
     Eyes on Lipinski's Rule of Five: A New "Rule of Thumb" for Physicochemical Design Space of Ophthalmic Drugs.
     J Ocul Pharmacol Ther. 2021 Dec 14. doi: 10.1089/jop.2021.0069.
     PubMed     Abstract available
     
     
     
181. TISI A, Zerti D, Genitti G, Vicentini MT, et al
     Characterization of SARS-CoV-2 Entry Factors' Expression in Corneal and Limbal Tissues of Adult Human Donors Aged from 58 to 85.
     J Ocul Pharmacol Ther. 2021 Dec 7. doi: 10.1089/jop.2021.0085.
     PubMed     Abstract available
     
     
     
182. RAJ SINGH TR
     Call for Special Issue Papers: Ocular Drug Delivery Technology Special Issue.
     J Ocul Pharmacol Ther. 2021;37:597.
     PubMed    
     
     
     
183. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:543-544.
     PubMed    
     
     
     
184. BUTOVICH IA, Yuksel S, Leonard B, Gadek T, et al
     Novel Lipids of the Rabbit Harderian Gland Improve Tear Stability in an Animal Model of Dry Eye Disease.
     J Ocul Pharmacol Ther. 2021;37:545-555.
     PubMed     Abstract available
     
     
     November 2021
185. CHALIMESWAMY A, Thanuja MY, Ranganath SH, Pandya K, et al
     Oxidative Stress Induces a Breakdown of the Cytoskeleton and Tight Junctions of the Corneal Endothelial Cells.
     J Ocul Pharmacol Ther. 2021 Nov 23. doi: 10.1089/jop.2021.0037.
     PubMed     Abstract available
     
     
     
186. LANDOWSKI M, Bowes Rickman C
     Targeting Lipid Metabolism for the Treatment of Age-Related Macular Degeneration: Insights from Preclinical Mouse Models.
     J Ocul Pharmacol Ther. 2021 Nov 17. doi: 10.1089/jop.2021.0067.
     PubMed     Abstract available
     
     
     
187. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:493-494.
     PubMed    
     
     
     
188. MANO F, Sakata S, Chang KC, Mano T, et al
     Effects of Zinc Acetate Hydrate Treatment on Serum Oxidative Stress Markers in Patients with Macular Drusen.
     J Ocul Pharmacol Ther. 2021;37:518-524.
     PubMed     Abstract available
     
     
     
189. LAKSMITA YA, Sidik M, Siregar NC, Nusanti S, et al
     Neuroprotective Effects of Citicoline on Methanol-Intoxicated Retina Model in Rats.
     J Ocul Pharmacol Ther. 2021;37:534-541.
     PubMed     Abstract available
     
     
     October 2021
190. CHEN L, Qu L, Gui Q, Wang S, et al
     Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage.
     J Ocul Pharmacol Ther. 2021 Oct 22. doi: 10.1089/jop.2021.0039.
     PubMed     Abstract available
     
     
     
191. SHELLEY H, Annaji M, Smith FT, Babu RJ, et al
     Difluprednate-Hydroxypropyl-beta-Cyclodextrin-Based Ophthalmic Solution for Improved Delivery in a Porcine Eye Model.
     J Ocul Pharmacol Ther. 2021 Oct 18. doi: 10.1089/jop.2021.0073.
     PubMed     Abstract available
     
     
     
192. LIMON U, Sezgin Akcay BI
     Efficacy of Intravitreal Dexamethasone After Combined Phacoemulsification and Pars Plana Vitrectomy for Diabetic Tractional Retinal Detachments.
     J Ocul Pharmacol Ther. 2021 Oct 15. doi: 10.1089/jop.2021.0072.
     PubMed     Abstract available
     
     
     
193. SARIGUL SEZENOZ A, Akkoyun I, Helvacioglu F, Haberal N, et al
     Antiproliferative and Mitochondrial Protective Effects of Apigenin in an Oxygen-Induced Retinopathy In Vivo Mouse Model.
     J Ocul Pharmacol Ther. 2021 Oct 15. doi: 10.1089/jop.2021.0046.
     PubMed     Abstract available
     
     
     
194. TADEPALLI S, Farhath HP, Sudhir RR, Padmanabhan P, et al
     Reliability of Aqueous Flare Measurements During Uveitis by a Spot Fluorometer.
     J Ocul Pharmacol Ther. 2021 Oct 13. doi: 10.1089/jop.2021.0053.
     PubMed     Abstract available
     
     
     
195. WU JH, Wang TH, Huang JY, Su CC, et al
     Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
     J Ocul Pharmacol Ther. 2021 Oct 4. doi: 10.1089/jop.2021.0071.
     PubMed     Abstract available
     
     
     
196. KOLLI A, Toris CB, Reed DM, Gilbert J, et al
     The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers.
     J Ocul Pharmacol Ther. 2021 Oct 4. doi: 10.1089/jop.2021.0068.
     PubMed     Abstract available
     
     
     
197. HAN IC, Burnight ER, Kaalberg EE, Boyce TM, et al
     Chimeric Helper-Dependent Adenoviruses Transduce Retinal Ganglion Cells and Muller Cells in Human Retinal Explants.
     J Ocul Pharmacol Ther. 2021 Oct 1. doi: 10.1089/jop.2021.0057.
     PubMed     Abstract available
     
     
     
198. KIM J, Moon TK, Yoon HJ, Ji YS, et al
     Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjogren's Syndrome.
     J Ocul Pharmacol Ther. 2021;37:472-478.
     PubMed     Abstract available
     
     
     
199. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:439-440.
     PubMed    
     
     
     
200. RASTMANESH R
     Aquaporin5-Targeted Treatment for Dry Eye Through Bioactive Compounds and Gut Microbiota.
     J Ocul Pharmacol Ther. 2021;37:464-471.
     PubMed     Abstract available
     
     
     
201. HOANG C, Nguyen AK, Nguyen TQ, Fang W, et al
     Application of Dimethyl Sulfoxide as a Therapeutic Agent and Drug Vehicle for Eye Diseases.
     J Ocul Pharmacol Ther. 2021;37:441-451.
     PubMed     Abstract available
     
     
     September 2021
202. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:383-385.
     PubMed    
     
     
     
203. YAO X, Chen C, Zhang J, Xu Y, et al
     Novel Peptide NT/K-CRS Derived from Kringle Structure of Neurotrypsin Inhibits Neovascularization In Vitro and In Vivo.
     J Ocul Pharmacol Ther. 2021;37:412-420.
     PubMed     Abstract available
     
     
     
204. PARK SA, Good KL, Thomasy SM, Kass PH, et al
     Effect of Withdrawing Chronic Topical Immune Modulating Treatment on Schirmer Tear Test Values in Dogs with Dry Eye Disease: Relevance to Dry Eye Studies.
     J Ocul Pharmacol Ther. 2021;37:394-398.
     PubMed     Abstract available
     
     
     
205. HERNANDEZ E, Taisne C, Lussignol M, Esclatine A, et al
     Commercially Available Eye Drops Containing Trehalose Protect Against Dry Conditions via Autophagy Induction.
     J Ocul Pharmacol Ther. 2021;37:386-393.
     PubMed     Abstract available
     
     
     July 2021
206. HUANG W, Wen Z, Saglam MS, Huang L, et al
     Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect.
     J Ocul Pharmacol Ther. 2021;37:321-330.
     PubMed     Abstract available
     
     
     
207. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:319-320.
     PubMed    
     
     
     
208. GAO X, Xiang Q, Fang J
     The Effect of Oral Vitamin A Supplementation on Chalazion in Young Children with Vitamin A Deficiency: A Pilot Study.
     J Ocul Pharmacol Ther. 2021;37:354-359.
     PubMed     Abstract available
     
     
     
209. FRIDMAN G, Sadlak N, Eliassi-Rad B, Desai MA, et al
     Real-World Clinical Impact of Netarsudil 0.02% at an Urban Safety-Net Hospital.
     J Ocul Pharmacol Ther. 2021;37:338-342.
     PubMed     Abstract available
     
     
     
210. ALSAIF A, Karam M, Al-Naseem A, Almuhanna A, et al
     Diclofenac Versus Dexamethasone Following Strabismus Surgery: A Systematic Review and Meta-Analysis.
     J Ocul Pharmacol Ther. 2021;37:343-353.
     PubMed     Abstract available
     
     
     June 2021
211. CHEWA RAJA JS, Singh S, Ismail F
     Pre-Emptive Topical Ketorolac Tromethamine 0.5% for Panretinal Photocoagulation.
     J Ocul Pharmacol Ther. 2021;37:313-317.
     PubMed     Abstract available
     
     
     
212. PAIVA MRB, Vasconcelos-Santos DV, Coelho MM, Machado RR, et al
     Licarin A as a Novel Drug for Inflammatory Eye Diseases.
     J Ocul Pharmacol Ther. 2021;37:290-300.
     PubMed     Abstract available
     
     
     May 2021
213. NOVACK GD
     Eyes on New Product Development: Regulations, Generics, and Disruptive Technologies.
     J Ocul Pharmacol Ther. 2021;37:191-192.
     PubMed    
     
     
     
214. UCAR F, Cetinkaya S
     The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery.
     J Ocul Pharmacol Ther. 2021;37:230-235.
     PubMed     Abstract available
     
     
     April 2021
215. SINGH RK, Binette F, Seiler M, Petersen-Jones SM, et al
     Pluripotent Stem Cell-Based Organoid Technologies for Developing Next-Generation Vision Restoration Therapies of Blindness.
     J Ocul Pharmacol Ther. 2021;37:147-156.
     PubMed     Abstract available
     
     
     March 2021
216. NOVACK GD
     Eyes on New Product Development.
     J Ocul Pharmacol Ther. 2021;37:73-74.
     PubMed    
     
     
     
217. OLIVERIO GW, Spinella R, Postorino EI, Inferrera L, et al
     Safety and Tolerability of an Eye Drop Based on 0.6% Povidone-Iodine Nanoemulsion in Dry Eye Patients.
     J Ocul Pharmacol Ther. 2021;37:90-96.
     PubMed     Abstract available
     
     
     January 2021
218. SHIN J, Rho CR, Hyon JY, Chung TY, et al
     A Randomized, Placebo-Controlled Phase II Clinical Trial of 0.01% or 0.02% Cyclosporin A with 3% Trehalose in Patients with Dry Eye Disease.
     J Ocul Pharmacol Ther. 2021;37:4-11.
     PubMed     Abstract available
     
     
     
219. BOZKURT E, Muhafiz E, Yayla M, Cinar I, et al
     The Relationship of the Urotensin-2 Level in the Aqueous Humor with Systemic Diseases and Pupil Size: Comparative Study.
     J Ocul Pharmacol Ther. 2021;37:45-51.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Ophthalmology is free of charge.